6185 — Cansino Biologics Income Statement
0.000.00%
Last trade - 00:00
- HK$5.14bn
- HK$3.67bn
- CNY345.18m
- 18
- 19
- 56
- 17
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 18.5 | 4,300 | 1,031 | 345 |
Cost of Revenue | |||||
Gross Profit | — | 4.74 | 3,003 | -187 | -876 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 200 | 419 | 2,388 | 2,400 | 2,380 |
Operating Profit | -200 | -401 | 1,912 | -1,369 | -2,035 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -157 | -397 | 1,937 | -1,184 | -1,979 |
Provision for Income Taxes | |||||
Net Income After Taxes | -157 | -397 | 1,907 | -965 | -1,967 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -157 | -397 | 1,914 | -909 | -1,483 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -157 | -397 | 1,914 | -909 | -1,483 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.698 | -1.72 | 7.73 | -3.68 | -6.01 |
Dividends per Share |